Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 22, 2024, titled "Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg".
Press Release May 22 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Theophylline Extended-Release Tablets in two dosages. This medication is intended for the treatment of asthma and chronic obstructive pulmonary disease. The tablets will be manufactured at Zydus's facility in Ahmedabad SEZ, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 17 2024
- Press Release May 11 2024
- Press Release May 09 2024
- Press Release May 04 2024
- Press Release Apr 26 2024
Later from Zydus Lifesciences
- Press Release May 24 2024
- Press Release Jun 14 2024
- Press Release Jun 28 2024
- Press Release Jul 04 2024
- Press Release Jul 10 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences